Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-21
2006-11-21
Richter, Johann R. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S002600, C514S640000
Reexamination Certificate
active
07138419
ABSTRACT:
A process for manufacturing bulk solutions and lyophilized pure α-aztreonam lysinate for large scale production of an inhalable aztreonam is disclosed, as is a pure α-aztreonam lysinate for inhalation. A dry powder or lyophilized pure α-aztreonam lysinate composition for inhalation is also disclosed.
REFERENCES:
patent: 4550105 (1985-10-01), Matsuo et al.
patent: 4572801 (1986-02-01), Matsuo et al.
patent: 4610824 (1986-09-01), Trüner
patent: 4673739 (1987-06-01), Matsuo et al.
patent: 4775670 (1988-10-01), Sykes et al.
patent: 4822788 (1989-04-01), Kishimoto et al.
patent: 4826973 (1989-05-01), Anderson et al.
patent: 4888998 (1989-12-01), Buzza et al.
patent: 4946838 (1990-08-01), Floyd et al.
patent: 5875776 (1999-03-01), Vaghefi
patent: 5994340 (1999-11-01), Maiti et al.
patent: 6054431 (2000-04-01), Horwitz et al.
patent: 6518239 (2003-02-01), Kuo et al.
patent: 2004/0009126 (2004-01-01), Pilkiewicz et al.
patent: 0297580 (1989-01-01), None
Bastin, R. J. et al. “Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities” Org. Proc. Res. & Develop. 2000, 4, 427-435.
The Dictionary of Modern Medicine, J.C. Segen, Ed. Parthenon Publishing Group: New Jersey, 1992, p. 517-518.
Brian E. Scully, M. B., et al., Use of Aztreonam in the Treatment of Serious Infections Due to Multiresistant Gram-Negative Organisms, IncludingPseudomonas Aeruginosa,The American Journal of Medicine, 78:251-261 (Feb. 1985).
John A. Bosso, et al., Efficacy of Aztreonam in Pulmonary Exacerbations of Cystic Fibrosis,The Pediatr. Infect. Dis. J., 6:393-397 (1987).
James L. Cook, M. D., Gram-Negative Bacillary Pneumonia in the Nosocomial Setting,The American Journal of Medicine, 88:3C-34S-37S.
A. Boccazzi, et al., The Pharmacokinetics of Aztreonam and Penetration into the Bronchial Secretions of Critically Ill Patients,Journal of Antimicrobial Chemotherapy, 23:401-407, (1989).
Harold C. Neu, M. D., Aztreonam Activity, Pharmacology and Clinical Uses, The American Journal of Medicine, 88:3C-2S-3C-6S.
Stephen C. Aronoff, et al.,In VitroActivities of Aztreonam, Piperacillin, and Ticarcillin Combined with Amikacin Against Amikacin ResistantPseudomonas aruginosaandP. cepaciaIsolates from Children with Cystic Fibrosis,Antimicrobial Agents and Chemotherapy, 25/2:279-280 (Feb. 1984).
John M. Matsen, et al., The Use of Aztreonam in the Cystic Fibrosis Patient,Pediatr. Infect. Dis. J., 8/9:S117-S119 (1989).
Lisa Saiman, MD, Antimicrobial Resistance AmongBurkholderia, Stentrophomonasand Alcaligenes Isolates Studied by the CF Eferal Center for Susceptibility and Synergy Testing, 1988 Cystic Fibrosis Conference, Symposium Session Summaries, 118-119 (1998).
Preston W. Campbell III, MD., et al., Use of Aerosolized Antibiotics in Patients with Cystic Fibrosis, Consensus Conference, pp. 775-789 (Sep. 1999).
Klaus Florey, Aztreonam,Analytical Profiles of Drug Substances, 17:1-39 (1988).
Ajit B. Thakur, et al., Interaction of Metronidazole with Antibiotics Containing the 2-Aminothiazole Moiety,Pharmaceutical Research, 8/11:1424-1429 (1991).
S. A. Ranadive, et al., Formation, Isolation and Identification of Oligomers of Aztreonam,European Journal of Pharmaceutical Sciences, 3:281-291 (1995).
Hiram C. Polk, Jr. MD, et al., Treatment of Pneumonia in Mechanically Ventilated Trauma Patients,Arch Surg., 132:1086-1092 (Oct. 1997).
Stephen P. Newman, Ph.D., Aerosol Deposition Considerations in Inhalation Therapy,Chest.88:2, 152S-160S (Aug. 1995).
Gerald C. Smaldone, et al., Aerosolized Antibiotics: Current and Future,Respiratory Care, 45/6:667-675 (Jun. 2000).
Thomas G. O'Riordan, MD, Inhaled Antimicrobial Therapy: From Cystic Fibrosis to the Flue,Respiratory Care, 45/7:836-845 (Jul. 2000).
Robert G. Bell, et al, Stability of Intravenous Admixtures of Aztreonam and Cefoxitin, Gentamicin, Metronidazole, or Tobramycin,American Journal of Hospital Pharmacy, 43:1444-1453 (Jun. 1986).
Michael J. James, et al., Stability of Intravenous Admixtures of Aztreonam and Ampicillin,American Journal of Hospital Pharmacy, 42:1095-1100 (May 1985).
Woo, M.S., et al., Use of Aerosolized Aztreonam in CF Lung Transplant Patients Colonized WithBurkholderia cepacia, 2002 Cystic Fibrosis Conference, 322/419 ★.
Petra Borsje, MD, et al., Aerosol Therapy in Cystic Fibrosis: A Survey of 54 CF Centers,Pediatric Pulmonology, 30:368-376 (2000).
Rafael Cantón, PD, PhD, Lung Colonization WithEnterobacteriaceaeProducing Extended-Spectrum β-Lactamases in Cystic Fibrosis Patients,Pediatric Pulmonology, 24:213-217 (1997).
S. Ballestero, et al.,Stenotophomonas maltophiliain Cystic Fibrosis Patients, 20thEuropean Cystic Fibrosis Conference, Brussels, Belgium (Jun. 18-21, 1995).
Sira Carrasco, et al., The General Approach to Cystic Fibrosis Pulmonary Infection in Spain,Cystic Fibrosis Pulmonary Infections: Lessons From Around The World, Chapter 18, pp. 223-230 (1996).
Desppina Daisy Frangolias, et al.,Burkholderia cepaciain Cystic Fibrosis,Am J of Respir Crit Care Med, 160:1572-1577 (1999).
John J. LiPuma, MD,Burkholderia cepacia, Management Issues and New Insights,Clinics in Chest Medicine, 19/3:473-486 (Sep. 1998).
Diane H. Johnson, MD, et al., Aztreonam,Medical Clinics of North America, 79/4:733-743 (Jul. 1995).
Dapena Fernandez J., et al., Inhaled Aztreonam Therapy in Patients With Cystic Fibrosis Colonized WithPseudomonas aeruginosa,Spanish Annals on Pediatrics, 40/3 (1994).
John A. Bosso, et al.,In VitroActivities of Combinations of Aztreonam, Ciprofloxacin, and Ceftazidme against Clinical Isolates ofPseudomonas aeruginosaandPseudomonas cepaciafrom Patients with Cystic Fibrosis,Antimicrobial Agents and Chemotherapy, 34/3:487-488 (Mar. 1990).
Carbonaro Peter
Duncan Iain
Montgomery Alan Bruce
Alstrum-Acevedo James H.
Corus Pharma, Inc.
Peters Verny Jones Schmitt & Aston, LLP
Richter Johann R.
Verny Hana
LandOfFree
Process for manufacturing bulk solutions and a lyophilized... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for manufacturing bulk solutions and a lyophilized..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for manufacturing bulk solutions and a lyophilized... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3693765